Metabolic cooperation between cancer and non-cancerous stromal cells is pivotal in cancer progression

Lopes‐Coelho, Filipa; Gouveia-Fernandes, Sofia; Serpa, Jacinta

doi:10.1177/1010428318756203

Cited by 24 publications

(17 citation statements)

References 199 publications

(313 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We believe this failure relies on the missing pieces to construct the entire angiogenic route. Considering that monocytes recruitment is a well-established step during carcinogenesis [96,97], we believe this recruitment favors tumor progression not only by differentiating into tumor associated macrophages (TAMs) [98][99][100][101], but also by acting as EPCs and differentiating into ECs. In a 3D co-culture system of breast cancer cells and monocytes, we detected hvWF positive cells that also expressed FN ( Figure 5A).…”

Section: Discussionmentioning

confidence: 99%

Monocytes as Endothelial Progenitor Cells (EPCs), Another Brick in the Wall to Disentangle Tumor Angiogenesis

Lopes‐Coelho

Silva

Gouveia-Fernandes

et al. 2020

Cells

Self Cite

View full text Add to dashboard Cite

Bone marrow contains endothelial progenitor cells (EPCs) that, upon pro-angiogenic stimuli, migrate and differentiate into endothelial cells (ECs) and contribute to re-endothelialization and neo-vascularization. There are currently no reliable markers to characterize EPCs, leading to their inaccurate identification. In the past, we showed that, in a panel of tumors, some cells on the vessel wall co-expressed CD14 (monocytic marker) and CD31 (EC marker), indicating a putative differentiation route of monocytes into ECs. Herein, we disclosed monocytes as potential EPCs, using in vitro and in vivo models, and also addressed the cancer context. Monocytes acquired the capacity to express ECs markers and were able to be incorporated into blood vessels, contributing to cancer progression, by being incorporated in tumor neo-vasculature. Reactive oxygen species (ROS) push monocytes to EC differentiation, and this phenotype is reverted by cysteine (a scavenger and precursor of glutathione), which indicates that angiogenesis is controlled by the interplay between the oxidative stress and the scavenging capacity of the tumor microenvironment.Over the last decade, different studies reported EPCs as essential in restoring injured vessels. EPCs belong to a subset of cells, arising from hematopoietic stem cells in bone marrow; upon pro-angiogenic stimuli, they proliferate, migrate, and differentiate into endothelial cells (ECs) [4][5][6]. Some reports addressing EPCs and disease, such as systemic sclerosis, showed contradictory and discrepant results about EPCs mobilization and differentiation; in part, because there is a lack of a precise panel of cell surface markers used for the characterization of this subset of cells [4][5][6][7][8][9][10]. In mouse embryonic vascular endothelium, erythro-myeloid progenitors (EMPs) can differentiate into ECs [11] and in a mouse model of carotid injury, monocytes (CD14 + cells) are capable of improving re-endothelialization [12]. In vivo and in vitro targeting of Tie2-monocytes decreases angiogenesis by abrogating EC proliferation [13][14][15] and an in vivo CCR2 (chemokine (C-C motif) receptor 2) knockout impairs monocytes recruitment and VEGFA (also named VEGF, vascular endothelial growth factor) expression, accompanied by a reduction in the angiogenesis rate [16]. The release of cytokines and pro-angiogenic factors (e.g., VEGFA, VEGFC, and VEGFD, TNFα (tumor necrosis factor α), IL-8 (interleukin-8), and FGF-2 (fibroblast growth factor-2), and extracellular matrix (ECM) modifying proteins (e.g., metalloproteinase-9 (MMP-9)) by macrophages enhances the tissue's ability to support capillary sprouting and vascular density [17,18]. The precise mechanism by which monocytes influence angiogenesis in tissue development, homeostasis, and diseases is not fully understood. However, different studies, have shown that under in vitro pro-angiogenic pressure, blood mononuclear cells can acquire endothelial markers and morphology [19][20][21]. In addition, in a previous study, we showed that some ECs sim...

show abstract

Section: Discussionmentioning

confidence: 99%

Monocytes as Endothelial Progenitor Cells (EPCs), Another Brick in the Wall to Disentangle Tumor Angiogenesis

Lopes‐Coelho

Silva

Gouveia-Fernandes

et al. 2020

Cells

Self Cite

View full text Add to dashboard Cite

show abstract

“…Metabolic remodeling leads to changes in biosynthetic and bioenergetic pathways not only in neoplastic cells but also in non-cancerous cells in the same microenvironment 25 . This cellular and molecular network sustains the high demand for energy and biomass production which are essential for cancer initiation and progression 26 . In breast and ovarian cancer cells it was stated that tumor microenvironment promotes tumor growth and provides a rationale for the development of targeted therapies that block cancer metabolism fueled by the microenvironment 27,28 .…”

Section: Discussionmentioning

confidence: 99%

Unraveling FATP1, regulated by ER-β, as a targeted breast cancer innovative therapy

Mendes

Lopes‐Coelho

Ramos

et al. 2019

Sci Rep

Self Cite

View full text Add to dashboard Cite

The biochemical demands associated with tumor proliferation prompt neoplastic cells to augment the import of nutrients to sustain their survival and fuel cell growth, with a consequent metabolic remodeling. Fatty acids (FA) are crucial in this process, since they have a dual role as energetic coins and building blocks. Recently, our team has shown that FATP1 has a pivotal role in FA transfer between breast cancer cells (BCCs) and non-cancerous cells in the microenvironment. We aimed to investigate the role of FATP1 in BCCs and also to explore if FATP1 inhibition is a promising therapeutic strategy. In patients’ data, we showed a higher expression of FATP1/SLC27A1 in TNBC, which correlated with a significant decreased overall survival (OS). In vitro, we verified that FA and estradiol stimulated FATP1/SLC27A1 expression in BCCs. Additionally, experiments with estradiol and PHTPP (ER-β antagonist) showed that estrogen receptor-β (ER-β) regulates FATP1/SLC27A1 expression, the uptake of FA and cell viability, in four BCC lines. Furthermore, the inhibition of FATP1 with arylpiperazine 5k (DS22420314) interfered with the uptake of FA and cell viability. Our study, unraveled FATP1 as a putative therapeutic target in breast cancer (BC).

show abstract

“…Adipocytes surrounding tumor cells exhibit phenotypical changes termed as adipocyte-derived fibroblasts (ADFs). ADFs enhance release fibronectin and collagen I, increase gene expression of adipokines and adipocytokines (TNF-α, IL-6 and IL-1β) which induce invasive abilities of breast tumor cells [185,186]. Among tumor microenvironment, endothelial cells are converted to fibroblast-like cells in the presence of TNF-α.…”

Section: Adipocytes Regulate Breast Cancer Via Released Cytokinesmentioning

confidence: 99%

The Effects of Adipocytes on the Regulation of Breast Cancer in the Tumor Microenvironment: An Update

Chu

Phuong

Tien

et al. 2019

Cells

View full text Add to dashboard Cite

Obesity is a global pandemic and it is well evident that obesity is associated with the development of many disorders including many cancer types. Breast cancer is one of that associated with a high mortality rate. Adipocytes, a major cellular component in adipose tissue, are dysfunctional during obesity and also known to promote breast cancer development both in vitro and in vivo. Dysfunctional adipocytes can release metabolic substrates, adipokines, and cytokines, which promote proliferation, progression, invasion, and migration of breast cancer cells. The secretion of adipocytes can alter gene expression profile, induce inflammation and hypoxia, as well as inhibit apoptosis. It is known that excessive free fatty acids, cholesterol, triglycerides, hormones, leptin, interleukins, and chemokines upregulate breast cancer development. Interestingly, adiponectin is the only adipokine that has anti-tumor properties. Moreover, adipocytes are also related to chemotherapeutic resistance, resulting in the poorer outcome of treatment and advanced stages in breast cancer. Evaluation of the adipocyte secretion levels in the circulation can be useful for prognosis and evaluation of the effectiveness of cancer therapy in the patients. Therefore, understanding about functions of adipocytes as well as obesity in breast cancer may reveal novel targets that support the development of new anti-tumor therapy. In this systemic review, we summarize and update the effects of secreted factors by adipocytes on the regulation of breast cancer in the tumor microenvironment.

show abstract

Metabolic cooperation between cancer and non-cancerous stromal cells is pivotal in cancer progression

Cited by 24 publications

References 199 publications

Monocytes as Endothelial Progenitor Cells (EPCs), Another Brick in the Wall to Disentangle Tumor Angiogenesis

Monocytes as Endothelial Progenitor Cells (EPCs), Another Brick in the Wall to Disentangle Tumor Angiogenesis

Unraveling FATP1, regulated by ER-β, as a targeted breast cancer innovative therapy

The Effects of Adipocytes on the Regulation of Breast Cancer in the Tumor Microenvironment: An Update

Contact Info

Product

Resources

About